[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"venous-thromboembolic-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:venous-thromboembolic-disease":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,39,70,103,139,163,190,214],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":5},"100301613","risk-factors-of-venous-thromboembolism-in-women-during-hormonal-exposure-100301613",false,"NCT03206372","Risk Factors of Venous Thromboembolism in Women During Hormonal Exposure","Risk of Venous Thromboembolism in First Degree Relatives of Women With or Without Venous Thromboembolism During Hormonal Exposure","FIT-H","Eligibility criteria:\n\n\\- Propositi with objectively confirmed proximal deep vein thrombosis (i.e. ultrasonography) or pulmonary embolism (i.e. lung scanning) in women (18 to 50 years) while on hormonal exposure.\n\nInclusion criteria\n\n* First-degree relatives (biological parents, brothers, sisters, children) of women of childbearing age 18-50 years (propositus) with a first MVTE in the hormonal setting and matched control women in the same hormonal setting who have never had MVTE, consenting to first-degree relatives being contacted to participate in the present study.\n* Written consent from propositi and family members.\n\nExclusion criteria\n\n* First-degree relatives whose propositus received preventive antithrombotic medication during pregnancy or contraception.\n* Family members of propositus who have had superficial or muscular venous thrombosis\n* No information can be obtained on first-degree relatives.\n* Family members under 16 years of age.\n* Vulnerable persons other than minors aged 16 to 18 (guardianship, curatorship).\n* Not affiliated to or not benefiting from a health insurance scheme.",true,"ALL","16 Years",{"count":21,"type":22},2640,"ESTIMATED","OBSERVATIONAL","Young women have an increased risk of venous thromboembolism (VTE) during hormonale exposure (estrogen-containing pill or pregnancy). In order to detect women at higher risk of VTE during hormonal exposure, thrombophilia testing is often performed in order to adapt contraception methods and\u002For to increases thromboprophylaxy during pregnancy. However, such practice is probably not accurate nor discriminent. Indeed, there are evidence that the impact of the familial history of VTE might be stronger than that of detectable inherited thrombophilia.\n\nThe \"FIT-H\" study is a cross-sectional study comparing the prevalence of previous venous thromboembolism in first-degree relatives of women (propositi) who had a first episode of venous thromboembolism in association with hormonal exposure with the prevalence of previous venous thromboembolism in first-degree relatives of women who did not have venous thromboembolism during a similar hormonal exposure.\n\nThe primary objective is to determine the association between the presence or the absence of VTE in young women during hormonal exposure and the presence or the absence of a previous episode of VTE in their first-degree relatives. Secondary objective is to determine the impact of associated inherited thrombophilia on the risk of VTE in first-degree relatives.",[26],"Venous Thromboembolic Disease","RECRUITING","2026-06-15",{"date":30,"type":31},"2026-06-16","ACTUAL",{"date":33,"type":31},"2017-10-24",{"date":35,"type":22},"2026-10-24",{"name":37,"class":38},"University Hospital, Brest","OTHER",{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":47,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":69},"100560297","thrombinography-in-pregnant-woman-and-in-vitro-action-of-low-molecular-weight-heparin-100560297","NCT06575309","THROmbinography in Pregnant Woman and in Vitro Action of Low Molecular Weight HEparin","Longitudinal Study of the in Vitro Action of Low Molecular Weight Heparin (LMWH) in Pregnant Women by Thrombinography","TROPHE","Inclusion Criteria:\n\n* Normal 1st trimester pregnancy\n* Age \\> 18\n\nExclusion Criteria:\n\n* Coagulation disease (Von Willebrand disease, known coagulation factor deficiency before pregnancy)\n* VTE history\n* First-degree family history of idiopathic VTE\n* Known biological risk factor for thrombosis Inherited deficiencies in coagulation inhibitors (antithrombin, protein C, protein S) Factor V Leiden polymorphism Prothrombin gene 20210G\\>A polymorphism Anti-phospholipid antibodies\n* Current anticoagulant use (VKA, heparins, etc.)\n* Gestational diabetes detected in the 1st trimester\n* Pre-existing type 1 and type 2 diabetes\n* History of pathological pregnancy Premature delivery Postpartum hemorrhage Preeclampsia\n* Hepatopathy\n* Obesity (BMI ≥ 30)\n* Infections (HIV, HBV, HCV...)\n* Autoimmune diseases\n* Pregnancy resulting from in vitro fertilization protocol\n* Multiple pregnancy\n* Patient under guardianship, curatorship or safeguard of justice\n* Patient not covered by a social security scheme\n* Patient deprived of liberty","FEMALE","18 Years","55 Years",{"count":51,"type":22},50,"Pregnancy is associated with major changes affecting all satges of hemostasis. Certain procoagulant factors are increased, such as factors VII, VIII, IX, X, XII, fibrinogen and Von Willebrand factor. Anticoagulant molecules are also affected by pregnancy, notably the protein C - protein S (PC - PS) system. overall, PC activity is little affected by pregnancy, increasing in the 2nd trimester and decreasing in the 3rd, but remaining within normal values. PS decreases from the first trimester of pregnancy, then progressively with gestational age. Antithrombin is stable during pregnancy.\n\nThe increased in most coagulation factors, combined with the decrease in concentrations of anticoagulant molecules, creates a state of relative hypercoagulability that protects women from bleeding during homostatic challenge of childbirth, but predisposes them to venous thromboembolic events.\n\nThe risk of venous thromboembolism (VTE) during pregnancy is increased compared to non-pregnant women of the same age. The post-partum period is also considered a thrombotic risk state for up to 12 weeks after delivery. Data on the incidence of VTE as a function of gestational age are contradictory: depending on the study, incidence may be stable or increase with advancing pregnancy.\n\nLow-molecular-weight heparin (LMWH) is the anticoagulant treatment of choice for prophylactic or curative treatment of VTE during pregnancy.\n\nPhysiological changes during pregnancy may alter the pharmacokinetic properties of LMWH. The increased volume of distribution and higher glomerular filtration rate may result in a reduced anticoagulant effect. On the other hand, the state of hypercoagulability probably counteracts the anticoagulant effect of LMWH. Nevertheless, the need to adjust doses during pregnancy remains controversial, and monitoring of anti-Xa activity is not clearly recommended. The optimal dose of LMWH in pregnant women, for both preventive and curative treatment, remains poorly understood. Initiation of treatment with LMWH therefore requires discussion of the dosage to be administered.\n\nAssessment of anticoagulation using more precise tools than those currently available on a routine basis could be useful in this context.\n\nThrombinography enables the amount of thrombin generated in the presence of coagulation activators to be assessed over time. This tool can be used to assess the impact of in vitro addition of different doses of LMWH in pregnant versus non-pregnant women and in the postpartum period.\n\nIn this pilot study, the investigators propose to evaluate thrombin generation, before and after in vitro addition of LMWH, in pregnant women longitudinally, during the 3 trimesters of pregnancy, postpartum and post-pregnancy.",[54,26],"Pregnant Women",[56,57,58,59],"Thrombography","Pregnancy","Postpartum","Low molecular weight heparins (LMWH)","2026-05-28",{"date":62,"type":31},"2026-05-29",{"date":64,"type":31},"2024-11-22",{"date":66,"type":22},"2027-12",{"name":68,"class":38},"University Hospital, Clermont-Ferrand",2,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":18,"minAge":48,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":79,"phases":80,"briefSummary":82,"conditions":83,"keywords":84,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":102},"100487460","phase-3-best-antithrombotic-therapy-in-patients-with-acute-venous-thromboembolism-while-taking-antiplatelets-100487460","NCT05627375","Best Antithrombotic Therapy in Patients With Acute Venous ThromboEmbolism While Taking Antiplatelets","BAT-VTE","Inclusion criteria\n\n* Signed informed consent\n* Patients with acute objectively confirmed symptomatic proximal deep-vein thrombosis (DVT) or pulmonary embolism (PE) (with or without deep-vein thrombosis). Proximal deep-vein thrombosis is defined as thrombosis involving at least the popliteal vein or a more proximal vein of the lower limb.\n* Indication of full-dose anticoagulant therapy for at least 3 months.\n* Prescription of antiplatelet therapy for secondary prevention of atherosclerotic cardiovascular diseases, at the time of VTE diagnosis\n* Life expectancy more than 3 months\n* Social security affiliation\n\nExclusion Criteria:\n\n* Unable to give informed consent\n* Active bleeding or a high risk of bleeding contraindicating anticoagulant treatment; a systolic blood pressure of more than 180 mm Hg or a diastolic blood pressure of more than 110 mm Hg\n* Anticoagulation for more than 5 days prior to randomization\n* Active pregnancy or expected pregnancy or no effective contraception\n* Isolated distal deep vein thrombosis\n* Antiplatelet therapy prescribed for primary prevention of cardiovascular disease\n* Indication to maintain a dual-antiplatelet therapy.\n* Triple positive antiphospholipid syndrome, with arterial thrombosis\n* Major cardiovascular and cerebrovascular event in the past 12 months for acute coronary syndrome, and in the past 6 months for cerebrovascular diseases and peripheral arterial diseases",{"count":78,"type":22},1400,"INTERVENTIONAL",[81],"PHASE3","Venous thromboembolism (VTE) and atherosclerotic cardiovascular disease share common risk factors and frequently coexist in the same patients.\n\nTheir management requires use of antithrombotic agents: anticoagulant therapy (AC) for secondary prevention of VTE recurrence, antiplatelet (AP) for secondary prevention of major adverse ischemic cardiovascular and cerebrovascular event (MACCE) in patients with atherosclerotic cardiovascular disease (coronary artery disease, atherosclerotic cerebrovascular disease, lower extremity peripheral arterial disease).\n\nSide effects of antithrombotic drugs are the 1st cause of emergency admission and hospitalization for an adverse drug reaction (mainly bleeding), and the combination of AC with AP strongly increases this risk.",[26],[85,86,87,88,89,90,91,92],"deep venous thrombosis","pulmonary embolism","anticoagulant","antiplatelet","Venous Thromboembolism","Direct oral anticoagulants","major adverse ischemic cardiovascular and cerebrovascular event","secondary prevention","2026-05-05",{"date":95,"type":31},"2026-05-08",{"date":97,"type":31},"2023-08-16",{"date":99,"type":22},"2028-12",{"name":101,"class":38},"Centre Hospitalier Universitaire de Saint Etienne",28,{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":18,"minAge":48,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":79,"phases":113,"briefSummary":115,"conditions":116,"keywords":123,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":134,"leadSponsor":136,"locationsCount":138},"100613720","reduced-dose-apixaban-and-rivaroxaban-versus-low-molecular-weight-heparin-in-patients-with-hematologic-malignancies-100613720","NCT07270263","Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies","Efficacy and Safety of Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies: A Prospective Randomized Study","HEM-DOAC","Inclusion Criteria:\n\n* Active hematologic malignancy at the time of initiation of systemic therapy, including multiple myeloma, myeloproliferative neoplasm, lymphoma or other hematologic cancer with a Khorana score ≥ 2 points (intermediate or high risk of venous thromboembolism, VTE)\n* Use of anticoagulant agents for primary thromboprophylaxis, including direct oral anticoagulants (DOACs) at reduced doses (apixaban 2.5 mg twice daily or rivaroxaban 10 mg once daily) or low-molecular-weight heparin (LMWH) (enoxaparin 40 mg subcutaneously once daily).\n\nExclusion Criteria:\n\n* Major bleeding within the last month (including gastrointestinal or intracranial bleeding).\n* Active major bleeding.\n* Hemoglobin concentration \\\u003C 8 g\u002FdL.\n* Thrombocytopenia with platelet count \\\u003C30 × 10⁹\u002FL.\n* ECOG performance status of 3 or 4.\n* Expected survival \\\u003C6 months.\n* History of mechanical heart valve or severe mitral stenosis.\n* Estimated glomerular filtration rate (eGFR) \\\u003C 25 mL\u002Fmin.\n* Hepatic impairment (ALT ≥ 3× upper limit of normal or bilirubin ≥ 2× upper limit of normal).\n* Acute coronary syndrome or ischemic stroke within the last 6 months.\n* Anticipated significant drug-drug interactions between DOACs and anticancer agents.\n* Known antiphospholipid syndrome (APS).",{"count":112,"type":22},100,[114],"NA","This study investigates the efficacy and safety of direct oral anticoagulants (DOACs) in comparison with standard low-molecular-weight heparin (LMWH) for the prevention of venous thromboembolism in patients with hematological malignancies. Eligible participants will be randomized to receive reduced-dose apixaban, reduced-dose rivaroxaban, or standard-dose LMWH. The primary objective is to evaluate the incidence of venous thromboembolism during a 6-month follow-up period. Secondary objectives include assessment of bleeding complications, overall survival, and treatment adherence. The results of this study may provide evidence for safer and more convenient thromboprophylaxis strategies in patients with blood cancers.",[117,118,119,26,120,121,122],"Lymphoma","Leukemia","Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma","VTE (Venous Thromboembolism)","PE - Pulmonary Embolism","Hematologic Malignacies",[124,125,126,89,127,128,129],"Apixaban","Rivaroxaban","Low-Molecular-Weight Heparin","Cancer-Associated Thrombosis","Hematologic Malignancies","Direct Oral Anticoagulants","2025-12-18",{"date":132,"type":31},"2025-12-26",{"date":64,"type":31},{"date":135,"type":22},"2026-12-31",{"name":137,"class":38},"Medical University of Gdansk",1,{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":143,"acronym":144,"eligibilityCriteria":145,"healthyVolunteers":11,"sex":18,"minAge":48,"maxAge":4,"enrollmentInfo":146,"targetDuration":4,"studyType":79,"phases":148,"briefSummary":150,"conditions":151,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":138},"100446114","phase-2-efficacy-of-prolonged-anticoagulation-for-primary-prevention-of-venous-thromboembolic-disease-in-autoimmune-hemolytic-anemia-a-prospective-phase-ii-randomized-multicenter-study-100446114","NCT05089227","Efficacy of Prolonged Anticoagulation for Primary Prevention of Venous Thromboembolic Disease in Autoimmune Hemolytic Anemia: a Prospective, Phase II, Randomized, Multicenter Study","API-AHAI","Inclusion Criteria:\n\n* Patient aged ≥ 18 years\n* Patient with a diagnosis of primary or secondary autoimmune hemolytic anemia (AIHA) (infections, hematologic diseases, systemic diseases), according to the following criteria:\n* Hemoglobin \\\u003C12 g\u002FdL\n* and decreased haptoglobin (\\\u003C0.4 g\u002FL)\n* and positive direct antiglobulin test (direct Coombs test) (IgG +\u002F- C3d)\n* Patient newly diagnosed or relapse\n* Patient with an estimated life expectancy of more than 6 months\n* Patient who provided free, written and informed consent\n\nExclusion Criteria:\n\n* Patients with immediate symptomatic VTE, confirmed by appropriate complementary examinations (venous Doppler of the lower limbs, thoracic angioscanner or pulmonary scintigraphy).\n* Patients on curative anticoagulation (venous thromboembolic disease, atrial fibrillation)\n* Patient on dual antiaggregation treatment\n* Patient with active bleeding\n* Patient with a known condition or lesion at risk of bleeding\n* Patient with ischemic stroke with hemorrhagic transformation within 6 months prior to inclusion\n* Patient on preventive anticoagulation for 14 days or more\n* Patient with a contraindication to apixaban:\n* Known hypersensitivity to the molecule or to any of the excipients,,\n* thrombocytopenia \\\u003C100 G\u002FL,\n* kidney failure (glomerular filtration rate \\\u003C 30 ml\u002Fmin\u002F1.73m²)\n* Active liver disease (liver failure defined as Factor V \\\u003C50% or INR \\>1.5, ALT elevation \\>2 times the upper limit of normal)\n* Patients receiving concomitant CYP3A4 inducers (rifampin, phenytoin, carbamazepine, phenobarbital, St. John's Wort) or CYP3A4 inhibitors (azole antifungals, HIV protease inhibitors), if these therapies cannot be discontinued or modified\n* Patients with a contraindication to enoxaparin:\n* allergy to the drug\n* history of heparin-induced thrombocytopenia\n* Patient with cold agglutinin-related AHAI (C3d-positive ADT alone with identification of cold agglutinins)\n* Patient with severe disorders of hemostasis:\n* hypofibrinogenemia \\\u003C 2 g\u002FL,\n* disseminated intravascular coagulation (APTT prolongation\\>1.2, and PT\\\u003C50%, and thrombocytopenia\\\u003C100 G\u002FL, and D-Dimer \\>500 µg\u002FL)\n* hemophilia\n* Patient whose clinical condition requires hospitalization in an intensive care unit\n* Patient who has already participated in the study\n* Patient not affiliated to national health insurance\n* Patient under legal protection (curatorship, guardianship)\n* Patient subject to a measure of legal protection\n* Pregnant, parturient or breastfeeding women\n* Patient with physiological capacity to procreate (having had her first menstrual period and not menopausal and not presenting permanent sterility (hysterectomy, bilateral salpingectomy, bilateral oophorectomy)) and unable to have effective contraception (i.e., provided by an estrogen-progestin oral contraceptive or progestogen, a contraceptive implant, an intrauterine device or a tubal ligation)\n* Patient of legal age who is unable to provide consent",{"count":147,"type":22},72,[149],"PHASE2","Autoimmune hemolytic anemia (AIHA) is a rare autoimmune disease (incidence \\\u003C1\u002F100,000 population) responsible for the destruction of red blood cells by the host immune system, notably through the action of autoantibodies.\n\nApart from complications related to anemia, the occurrence of venous thromboembolism (VTE) in this population is frequent, estimated at 20-27%. The risk of VTE is highest during the period of hemolysis, especially during the first 3 months after the diagnosis of AIHA. This risk is 7.5 \\[4.7; 12.0\\] times greater than in the general population. No clinical predictive factor for VTE was identified and the usual factors (cancer, previous VTE, bed rest \\>3 days, surgery, age \\>70 years, heart or respiratory failure, myocardial infarction, stroke, obesity, hormone replacement therapy) were not considered. Several biological risk factors have been suggested (depth of anemia, bilirubin level, leukocyte count, antiphospholipid antibodies) but have not been confirmed in other studies.\n\nAIHA is therefore a risk factor for VTE in its own right, and the National Diagnostic and Care Protocol (NDCP) recommends the implementation of VTE prevention during acute hemolysis (Grade C). However, the value of this prophylaxis has never been prospectively evaluated and its duration is empirical. In practice, low-molecular-weight heparin (LMWH) is generally used during \"flare-ups\" of AIHA (diagnosis and relapse) in hospitalized patients, but is rarely continued beyond the hospital phase when VTE also occurs in ambulatory patients.\n\nThus, we hypothesize that prolonged preventive anticoagulation during the 12-week risk period following diagnosis or relapse of AIHA could decrease the incidence of VTE.\n\nIn orthopedic surgery, this strategy has been proven to decrease VTE from 50% to 10-15%. In certain high-risk medical situations, prolonged prophylaxis with apixaban has been shown to decrease the occurrence of VTE from 10.2% to 4.2% in solid cancers4 and from 4-11% to 2% in myeloma.",[152,26,153],"Prolonged Anticoagulation","Autoimmune Hemolytic Anemia","2025-12-16",{"date":156,"type":31},"2025-12-22",{"date":158,"type":31},"2022-02-03",{"date":160,"type":22},"2028-08",{"name":162,"class":38},"Centre Hospitalier Universitaire Dijon",{"id":164,"slug":165,"hasResults":11,"nctId":166,"briefTitle":167,"officialTitle":168,"acronym":4,"eligibilityCriteria":169,"healthyVolunteers":11,"sex":18,"minAge":170,"maxAge":4,"enrollmentInfo":171,"targetDuration":4,"studyType":79,"phases":173,"briefSummary":174,"conditions":175,"keywords":179,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":188,"locationsCount":138},"100378717","chips-vte-study-in-hospitalized-patients-to-prevent-hospital-acquired-venous-thromboembolism-100378717","NCT04211181","CHIPs-VTE Study in Hospitalized Patients to Prevent Hospital-Acquired Venous Thromboembolism","Effect on Thromboprophylaxis Among Hospitalized Patients Using a System-wide Multifaceted Quality Improvement Intervention: Rationale and Design for a Multicenter Cluster Randomized Clinical Trial in China","Inclusion Criteria:\n\n1. Aged ≥14 years\n2. Have an expected hospital stay ≥72 hours for medical and\u002For surgical treatment\n3. Written informed consent\n\nExclusion Criteria:\n\n1. Inability to be followed-up at until 3 months after randomization\n2. Have participated in similar trials or are undergoing other clinical trials\n3. Refuse or are unable to give informed consent\n4. VTE identified on CTPA or lower extremity vein ultrasound at or any time before enrollment\n5. Requiring a full dose of anticoagulant treatment (e.g., recent VTE, atrial fibrillation).","14 Years",{"count":172,"type":22},5800,[114],"Although pharmacologic and mechanical methods to prevent VTE are safe, effective, cost-effective, and advocated by authoritative guidelines,many studies continue to demonstrate that these preventive methods are significantly underutilized, especially in China.A number of quality improvements (QI) program have been established in several countries or hospitals.However,no exit effective protocol has been demonstrated well enough or adequate to drive breakthrough levels of improvement. A reliable and practical QI that can support hospitals or physicians in China is warranted.To evaluate the multifaceted quality improvement intervention effect in clinical setting, we will conduct a cluster-randomized clinical trial among China PUlmonary Thromboembolism REgistry Study (CURES) group, aiming to test whether it's applicable to real-world practice in China.\n\nA multicenter, two-arms, open-label clinical trial has been designed to determine whether the system-wide multifaceted intervention could increase the rate of at-risk participants who received prophylaxis (RP) and decrease the incidence of any hospital-associated VTE in 90 days during and after hospital admission. .Selected hospital will be regarded as a cluster and randomized into interventional or control group.In interventional group, eligible hospitalized patients will receive a variety of the multifaceted quality improvement(QI) interventions since admitted in hospital.In control group, patients will receive no more than common recommended care or an existing policy.The primary outcomes are the proportion of appropriate prophylaxis in hospitalized patients and the incidence of HA-VTE in 90 days after hospital admission.",[26,176,89,177,178],"Pulmonary Embolism","Deep Venous Thrombosis","Quality Improvement",[180,89,181],"Quality improvement","Hospital Associated-VTE","2025-09-11",{"date":184,"type":31},"2025-09-17",{"date":186,"type":31},"2025-08-01",{"date":135,"type":22},{"name":189,"class":38},"China-Japan Friendship Hospital",{"id":191,"slug":192,"hasResults":11,"nctId":193,"briefTitle":194,"officialTitle":194,"acronym":195,"eligibilityCriteria":196,"healthyVolunteers":11,"sex":18,"minAge":48,"maxAge":4,"enrollmentInfo":197,"targetDuration":199,"studyType":23,"phases":4,"briefSummary":200,"conditions":201,"keywords":202,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":138},"100594215","cohort-for-monitoring-patients-with-venous-thromboembolic-disease-100594215","NCT07016542","Cohort for Monitoring Patients With Venous Thromboembolic Disease","CoMTEV","Inclusion Criteria:\n\n1. Any patient over 18 years of age who has experienced at least one venous thromboembolic episode:\n\n   * Deep vein thrombosis confirmed by Doppler ultrasound or CT venography,\n   * Pulmonary embolism confirmed by CT angiography, ventilation\u002Fperfusion scan, or confirmed DVT episode with respiratory signs consistent with PE.\n2. Hospitalization in the Internal Medicine Department\n3. Consultation by an Internal Medicine physician\n4. File presented at the thrombosis multidisciplinary meeting\n\nExclusion Criteria:\n\nThrombosis not meeting the inclusion criteria (cerebral venous thrombosis, mesenteric)",{"count":198,"type":22},2000,"12 Years","Venous thromboembolic disease is a common pathology in the general population (1.5\u002F1000), the prognosis of which depends in particular on the risk of recurrence. This risk depends essentially on whether the thrombotic episode was provoked or not. Thus, patients who present a thromboembolic event without any contributing factor have a high risk of recurrence, which encourages clinicians to continue anticoagulant treatment for a long time. However, anticoagulant treatment is the leading cause of hospitalization for iatrogenic causes and the leading cause of iatrogenic mortality. The benefit-risk balance of treatment must be evaluated regularly, which requires a good knowledge of the risk factors for thrombotic recurrence and the risk factors for hemorrhage.",[26],[203,204],"risk of thrombotic recurrence","hemorrhagic risk factors","2025-06-04",{"date":207,"type":31},"2025-06-11",{"date":209,"type":31},"2019-11-18",{"date":211,"type":22},"2032-06-01",{"name":213,"class":38},"University Hospital, Rouen",{"id":215,"slug":216,"hasResults":11,"nctId":217,"briefTitle":218,"officialTitle":219,"acronym":220,"eligibilityCriteria":221,"healthyVolunteers":11,"sex":18,"minAge":48,"maxAge":222,"enrollmentInfo":223,"targetDuration":4,"studyType":79,"phases":225,"briefSummary":226,"conditions":227,"keywords":231,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":237,"lastUpdatePostDateStruct":238,"startDateStruct":240,"completionDateStruct":242,"leadSponsor":244,"locationsCount":138},"100533955","alerting-providers-at-patient-hospital-discharge-to-consider-prescribing-rivaroxaban-to-reduce-venous-thromboembolism-100533955","NCT06232551","Alerting Providers at Patient Hospital Discharge to Consider Prescribing Rivaroxaban to Reduce Venous Thromboembolism","eVTE (Electronic Venous Thromboembolism): A Cluster, Randomized, Step-wedge Type II Hybrid Study of an Alert Recommending Extended Duration Thromboprophylaxis for At-risk Discharging Medical Patients to Prevent VTE.","eVTE","Inclusion Criteria:\n\n* Discharging clinician must be in one of the following iCentra electronic health record (Cerner, Kansas City, MO) positions:\n\n  * Physician, nurse practitioner, or physician assistant hospitalist\n  * Physician internal medicine\n  * Physician family medicine\n* Patient age ≥ 18 years.\n* The encounter must be inpatient.\n* A signed hospital discharge order must be present.\n* eVTE target population criteria (increased venous thromboembolism risk, low bleeding risk) must be met\n\nExclusion Criteria:\n\n* Pregnant during encounter\n* Discharge order completed by ineligible clinician type\n* Exclude all cases where the patient is being actively prescribed and intended to be discharged on the following qualifying anticoagulant medications, regardless of dose form or dosing regimen (i.e., they have an active prescription for one of these medications):\n\n  * Apixaban\n  * Dabigatran\n  * Dalteparin\n  * Enoxaparin\n  * Edoxaban\n  * Betrixaban\n  * Fondaparinux\n  * Rivaroxaban\n  * Warfarin\n* Creatinine clearance \\\u003C30 milliliters\u002Fminute based on last-available eligible serum creatinine value preceding discharge\n\n  * Estimated creatine clearance based on actual body weight (preferred) ((140 - age years) \\* measured weight kilograms) \u002F (72.0 \\* serum creatine milligrams\u002Fdeciliter) (\\*0.85 if female)) = milliliters\u002Fminute\n  * If measured body weight not available, then based on ideal body weight ((140 - age years) \\* ideal body weight kilograms) \u002F (72.0 \\* serum creatine milligrams\u002Fdeciliter) (\\*0.85 if female)) = milliliters\u002Fminute","110 Years",{"count":224,"type":22},152000,[114],"A new algorithm derived from only patient age and components of the complete blood count and basic metabolic panel can identify patients discharged from the hospital who may benefit from a blood thinner (called rivaroxaban) to decrease their risk of blood clots, and for whom the risk of bleeding is minimal.\n\nThe purpose of this study is to evaluate the use of a pop-up alert, which will be seen by clinicians when a discharging patient has been identified as being someone for whom the risk of blood clots is high, but for whom bleeding risk is estimated to be low.\n\nThe pop-up alert will be enabled in a sequential fashion for each group of hospitals in 1 month blocks. We will look to see if the pop-up alert changes the number of patients who receive rivaroxaban. We will also measure the outcomes of blood clots and bleeding among all discharging patients.",[26,228,229,230],"Pulmonary Embolism and Thrombosis","Deep Vein Thrombosis","Hospitalism",[232,233,234,235,236],"post-discharge","extended duration thromboprophylaxis","rivaroxaban","direct oral anticoagulant","medical patient","2024-07-15",{"date":239,"type":31},"2024-07-17",{"date":241,"type":31},"2024-06-01",{"date":243,"type":22},"2025-09-30",{"name":245,"class":38},"Scott C. Woller, MD"]